BNET Industries
Amgen Inc. (AMGN) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $14.7B
- Profit
- Dec 31 2007
- $3.1B
- Market Cap
- Jul 23 2008
- $58.7B
Latest News and Analysis
Wyeth Profit Falls 7 Percent, But Beats Estimates
NEW YORK (Reuters) - Wyeth WYE on Wednesday said second-quarter earnings fell 7 percent, hurt by generic forms of its Protonix ulcer drug, although results beat estimates as they were helped by its vaccine for childhood infections and a drug for...
Amgen Looking Attractive Heading into Earnings
Steve Patterson submits: Amgen Inc AMGN is looking very attractive heading into earnings with the additional good news of NPlate being approved by the Food and Drug Administration on Wednesday or Thursday. Strong Volume by Steve Patterson
Monday Options Outlook: SGP, MRK, AZN, AMGN, CELG, BBH, BAC, KRE, XLF
Rebecca Engmann Darst co-authored this article. Schering-Plough SGP ? Shares are down 11.2% to $19.04 after the company announced that it would postpone its results until after the bell pending the release of new data surrounding its drug Vytorin. Implied volatility shot up 62% to 75.9% on...
Big Biotech Booms But IBB Falls Flat
Don Dion submits: Shares in the biotech firm Amgen AMGN shot up Monday morning after the firm announced major developments for two of its products: Nplate, a drug designed to treat a rare form of blood-platelet deficiency, received final approval from the FDA, and the results of a...
Amgen to Pay J&J $200 Million to Settle Antitrust Suit
LOS ANGELES (Reuters) - Amgen Inc AMGN said on Friday it will pay Johnson & Johnson JNJ $200 million to settle litigation alleging drug discounts offered by Amgen to cancer clinics violated antitrust laws. Amgen, the world's largest biotechnology company in terms ...
Pfizer, Merck and Lilly Partner to Get "Enlightened"
Mike Huckman submits: Big pharma makes strange bedfellows. Pfizer PFE, Merck MRK, and Eli Lilly LLY announced yesterday morning that they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC ("Venture Creation," the website says, not "Venture Capital") firm...
Biotech's New Blockbusters -- Oh, Really?
FierceBiotech's Maureen Martino has produced a "special report" that four biotech drugs poised for approval later this year could be "the next generation of biologic blockbusters" -- that is, treatments that not only pull in more than $1 billion in annual sales, but which "could offer real breakthroughs for patients"...
What's the Story on Amgen Shorts?
Mike Huckman submits: When combing through Barron's over the weekend I always make it a point to check out the "Short Interest" tables when they appear. I'm curious, in particular, about the ups and downs in Dendreon DNDN. Right now it's 39th on Barron's list of the Top-40 largest...
S&P 500 Stocks Furthest Above and Below Their 50-Day Moving Averages
Hickey and Walters Bespoke submit: Below we highlight stocks in the S&P 500 that are currently trading the furthest above and below their 50-day moving averages. As shown, Massey Energy MEE is the furthest above its 50-day in the index at 39.47%. MEE is also the best performing...
Pharma's Future Leaders -- Or Its Pallbearers
Given the challenges facing Big Pharma -- expiring patents, waning drug pipelines, the imploding blockbuster model, and increasing political pressure on its marketing practices -- it's hard not to wonder sometimes just who in their right minds would want to lead its giant but fragile companies over the next decade...
Lowest P/E Ratios in the Nasdaq 100
Hickey and Walters Bespoke submit: Below we highlight the 25 stocks in the Nasdaq 100 with the lowest estimated P/E ratios for the current year. As shown, Flextronics FLEX currently has the lowest at 8.93, followed by CDNS, AMGN and LRCX. One of the more surprising valuations on...
What's Ailing the Pharmaceutical Sector?
Marc Courtenay submits: Lou Basenese, The Associate Editor of the Oxford Club is a respected friend and colleague. With his permission, I want to share what he recently wrote on the pharmaceuticals drug companies. He has some very interesting observations and recommendations that we should all take to heart. His...
Amgen, Inc. Q1 2008 Earnings Call Transcript
Amgen, Inc. Q1 2008 Earnings Call Transcript
Amgen, Inc. Q4 2007 Earnings Call Transcript
Amgen, Inc. Q4 2007 Earnings Call Transcript
Amgen Q3 2007 Earnings Call Transcript
Amgen Q3 2007 Earnings Call Transcript
Daily Dispatch: Countrywide Financial, Amgen, Netflix, and J.C. Penney
Countrywide Financial Corp. tapped its entire $11.5 billion credit line to offset a surge in loan defaults and to address the company's liquidity crunch. CFC plans to originate mostly conforming loans, which are backed by government-sponsored entities like Fannie Mae, from this point forward, nearly eliminating its riskier...
Amgen Q2 2007 Earnings Call Transcript
Amgen Q2 2007 Earnings Call Transcript
Amgen Q1 2007 Earnings Call Transcript
Amgen Q1 2007 Earnings Call Transcript
Amgen Q4 2006 Earnings Call Transcript
Amgen Q4 2006 Earnings Call Transcript
Amgen Q3 2006 Earnings Call Transcript
Amgen Q3 2006 Earnings Call Transcript
- Next »
- page 1 of 2
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Finance (14 results)
- Financial Accounting (13 results)
- Call Transcript (12 results)
- Earnings (12 results)
- Seeking Alpha (12 results)
- Merck & Co. Inc. (4 results)
- Biotech (4 results)
- Sales Strategy (3 results)
- Sales Force Management (3 results)
- Sales (3 results)
- US Market (3 results)
- Celgene Corp. (3 results)
- Healthcare (3 results)
- Incorporated: 1980
- CEO: Mr. Kevin W. Sharer
Amgen is a biotechnology company that is engaged in discovering, developing, manufacturing and marketing human therapeutics based on advances in cellular and molecular biology. Co. operates in one business segment, human therapeutics, in which it markets human therapeutic products in the areas of supportive cancer care, nephrology, inflammation and oncology. Co.'s principal products include Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim), NEUPOGEN® (Filgrastim), EPOGEN® (Epoetin alfa) and Enbrel® (etanercept). Co. markets its principal products to healthcare providers including clinics, dialysis centers, hospitals and pharmacies.
Key Competitors
Amgen Inc. Company Info
Board of Directors
Mr. Kevin W. Sharer
Chairman
Admiral J. Paul Reason
Mr. Leonard D. Schaeffer
Dr. David Baltimore
Mr. Frank J. Biondi Jr.
Mr. Jerry D. Choate
Dr. Vance D. Coffman
Mr. Frederick W. Gluck
Mr. Frank C. Herringer
Dr. Gilbert S. Omenn M.D.
Ms. Judith C. Pelham
Contact Information
One Amgen Center Drive
Thousand Oaks, CA
805 447-1000
NAICS Code
Biological Product (except Diagnostic) Manufacturing: 325414Brought to you by IBMSponsored Resources
